OncoMatch

OncoMatch/Clinical Trials/NCT03025477

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Is NCT03025477 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including CC0 - Carboplatin (IV) - Paclitaxel (IV) and CC0 - Cisplatin (IP) - Epirubicin (IV) for ovarian cancer, epithelial.

Phase 2RecruitingGroupe Hospitalier Diaconesses Croix Saint-SimonNCT03025477Data as of Jun 2026Location: France

Treatment: CC0 - Carboplatin (IV) - Paclitaxel (IV) · CC0 - Cisplatin (IP) - Epirubicin (IV) · CC>0 - Carboplatin (IV)- Paclitaxel (IV) · CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

CC0 - Carboplatin (IV) - Paclitaxel (IV)CC0 - Cisplatin (IP) - Epirubicin (IV)CC>0 - Carboplatin (IV)- Paclitaxel (IV)CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)

Cancer type

Ovarian Cancer

Disease stage

Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)

Excluded: Stage FIGO STAGE IV EXTRA-ABDOMINAL DISEASE

Metastatic disease required

advanced (FIGO stage III or IV)... Exclusion: FIGO stage IV extra-abdominal disease, with the exception of lymph nodes and pleural invasion

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 75
Female only

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

Lab requirements

Blood counts

neutrophils > 1500/mm3, platelets > 150 000/mm3

Kidney function

creatinine clearance mdrd ≥ 60 ml/min

Cardiac function

left ventricular ejection fraction ≥ 50% before chemotherapy initiation

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT03025477 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage FIGO STAGE III or FIGO STAGE IV is required (metastatic disease required).

Is there an age limit?

Yes. Patients must be 75 years or younger.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify